Objective: Tartrate-resistant acid phosphatase (TRAP) expressed by adipose tissue macrophages (ATMs) induces mice obesity and human adipocyte differentiation in vitro. This study aimed to investigate whether TRAP was secreted differently from human obese versus lean adipose tissues and to identify the cellular source of adipose tissue TRAP. Design: Subcutaneous adipose tissues obtained from healthy subjects. Enzyme-linked immunosorbent assays (ELISAs) for total (5a þ 5b) and cleaved TRAP (5b) were used. TRAP secretion was determined in adipose tissue biopsies, and mRNA expression was studied in cell types isolated from the same. Subjects: Results of 24 lean and 24 obese women (in vitro) and 8 subjects (in vivo) were compared. The main outcome measurements were TRAP expression and secretion in vitro and in vivo. Results: In-house total TRAP ELISA showed high sensitivity and a coefficient of variance of 11%. Adipose secretion of total TRAP was linear in vitro with time and was evident in vivo. Total TRAP secretion in vitro was similar in lean and obese women expressed per unit weight of the adipose tissue but correlated positively with the number/size of adipocytes (Pp0.01) and with adipose secretion of tumor necrosis factor-a and interleukin-6 (Po0.01). TRAP 5b was not secreted from the adipose tissue. ATMs displayed highest cellular expression of TRAP mRNA in adipose tissue cells derived from lean or obese women. Conclusions: TRAP is a novel human adipokine produced by macrophages and secreted from the subcutaneous adipose tissue in vivo and in vitro. Secretion is linked to the size and number of adipocytes, as well as to concomitant secretion of inflammatory mediators, suggesting that TRAP is involved in fat accumulation and adipose inflammation.
Introduction
Tartrate-resistant acid phosphatase (TRAP; EC 3. 1.3.2) is a metalloprotein with a redox active diiron center. 1 It is synthesized as the monomeric isoform TRAP 5a, which can either be secreted 2, 3 or proteolytically processed creating isoform TRAP 5b. 4 TRAP is highly expressed by osteoclasts and by sub-populations of macrophages, epithelial cells and neurons. 5, 6 In vivo, TRAP 5b has previously been proposed to function as a generator of reactive oxygen species and as a protein phosphatase regulating the bioactivity of osteopontin. [7] [8] [9] Recently, we showed that TRAP 5a, but not TRAP 5b, induces obesity in mice and is increased in the adipose tissue of obese humans. 10 Furthermore, TRAP 5a, but not TRAP 5b, induces both proliferation and differentiation of mouse and human adipocyte precursors in vitro. This suggests that TRAP 5a is important for adipogenesis, and that the major source in the adipose tissue seems to be adipose tissue macrophages (ATMs). Recently, it was also shown that serum levels of TRAP 5a were increased in obese humans but, in contrast to proinflammatory cytokines, not normalized by exercise.
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In human serum, TRAP 5a, which is a proposed marker of chronic inflammation, 12 is suggested to originate mainly from macrophages and levels are increased in rheumatoid arthritis. 13 On the other hand, serum levels of TRAP 5b are suggested to originate predominantly from osteoclasts and are increased under conditions with increased bone resorption, for example, post-menopausal osteoporosis. 14 It is well established that obesity is characterized by lowgrade inflammation in which increased numbers of macrophages accumulate in mouse 15, 16 and human 17 adipose tissues. These ATMs are believed to be involved in the development of insulin resistance and inhibition of adipogenesis. 18 However, the macrophage population is not homogenous but rather exhibits great potential of diverse activation/stimulation. Among these, the M1 macrophage, present in diet-induced obesity, secretes, for example, tumor necrosis factor-a (TNFa), interleukin (IL)-1 and IL-6, whereas the M2a macrophage, present in lean and diet-induced obesity mice, secretes, for example, IL-10. [19] [20] [21] [22] Conditioned media from mouse derived M1 -but not M2a -stimulated macrophages that inhibits adipogenesis in vitro, 19 indicating different effects of ATM sub-populations on adipocytes. This possible functional difference within the macrophage population could indicate that secretion of macrophage-derived anti-adipogenic factors, such as TNFa, and that of proadipogenic factors, such as TRAP 5a, originate from different macrophage sub-populations. In humans, ATMs do not seem to be as strictly polarized as compared with murine models, an observation that might be related to the chronicity of the inflammatory process associated with human obesity. 23, 24 So far, only two studies have investigated the expression and function of TRAP in the adipose tissue. 10, 11 A number of clinically relevant issues are still unsolved such as: whether TRAP is expressed in adipose tissue cells other than ATMs; which isoforms of TRAP are secreted from the adipose tissue and whether the secretion of TRAP is correlated with that of other known cytokines/adipokines from the adipose tissue? This study was designed to answer these questions by investigating human subcutaneous adipose tissues derived from lean and obese women.
Materials and methods

Subjects
This study on different cell populations in the adipose tissue was conducted on healthy women (mean body mass index (BMI) ¼ 28.3 ± 0.8 kg m
À2
, BMI range from 20.8 to 36.2, mean age ¼ 41.7 ± 1.5 years, range from 26 to 68) undergoing elective surgical procedures of fat removal for aesthetic purposes. Time course experiments were conducted on abdominal subcutaneous adipose tissues obtained from healthy subjects (BMI ¼ 37.6±5.9 kg m
; n ¼ 4, adipocyte volume ¼ 837±49 pl; n ¼ 3). Tissues were obtained as a waste product of cosmetic liposuction or plastic surgery of the abdominal wall. They were not selected on the basis of age, sex or BMI.
In vivo release of TRAP was conducted on six men and two women recruited at the Department of Medicine (Umeå University Hospital, Umeå, Sweden). This protocol and the study population have been described elsewhere. 25 In brief, abdominal subcutaneous vein and arterialized samples were obtained in the morning after an overnight fast, 25 and serum samples were stored at À80 1C until further use. Studies on lean and obese subjects were conducted on healthy women. Obesity was defined as BMI 430 kg m À2 . A total of 22 women were lean (BMI ¼ 22.7±1.5 kg m
, age 35±9 years) and 24 were obese (BMI ¼ 37.1±7.5 kg m
, age 35 ± 7 years). Mean fat cell size was markedly increased in obese (830±141 pl) than in non-obese women (427±165 pl). After an overnight fast, a venous blood sample was drawn in the morning and serum kept frozen at À70 1C. Thereafter, the abdominal subcutaneous adipose tissue was obtained by needle biopsy under local anesthesia and immediately used for secretion experiments. Adipose tissue morphological value was calculated as described previously. 26 This value reflects fat cell size in relation to total fat mass. A negative value is indicative of many small fat cells (hyperplasia). A positive value reflects few but large fat cells (hypertrophy). Morphology values are quantitative, that is, the larger they are, the more pronounced is the hyperplasia/hypertrophy. For fluorescence-activated cell sorting analysis, the number of subjects was n ¼ 3 with a BMI of 30.1 ± 5.5 kg m
. All studies were approved by the local ethics committee. Studies were explained in detail to each subject and their written consent was obtained.
Measurement of TRAP expression in different cell populations from human adipose tissues
Cells from the stroma-vascular fraction (SVF) and mature adipocytes from human white adipose tissue were obtained after collagenase digestion and cell sorting using Easysep magnetic nanoparticles as described previously. 23 The different cell populations obtained from the SVF were adipocyte progenitor cells defined as CD34
þ and cells negative for CD34, CD31 and CD14.
RNA was extracted using the RNeasy kit obtained from Qiagen (Sollentuna, Sweden). RNA concentrations were measured by a fluorometric assay (Ribogreen; Invitrogen, Cergy Pontoise, France) and reverse transcribed using the Superscript II kit (Invitrogen). Reverse transcription was also performed without the Superscript enzyme on RNA samples to ensure the absence of contaminating genomic DNA. Primers for human TRAP were obtained from Applied Biosystems (Hs 00356261-m1; Courtaboeuf, France). The amplification reaction was performed in duplicate on 15 ng cDNA samples in a final volume of 20 ml in 96-well reaction plates (Applied Biosystems) in a GeneAmp 7500 detection system (Applied Biosystems). All reactions were performed under the same conditions: 50 1C for 2 min, 95 1C for 10 min, 40 cycles of 95 1C for 15 s and 60 1C for 1 min. Results were analyzed using the GeneAmp 7500 software, and all the values were normalized to the levels of 18S rRNA.
TRAP secretion in the human adipose tissue P Lång et al Flow-cytometry analysis of TRAP-expressing cells from human adipose tissues A total of 500 000 cells from the SVF fraction of the human adipose tissue in 100 ml phosphate-buffered saline containing 1 mM ethylenediaminetetraacetic acid and 0.5% bovine serum albumin were stained with mouse anti-human CD14-PE or with isotype control (BD Bioscience, Le-Pont-deClaix, France) for 25 min at 4 1C. After washing and fixation, cells were permeabilized with ice-cold ethanol for 30 min on ice. After washing, cells were stained with rabbit anti-rat total TRAP (5a and 5b; 1:50) 27 or rabbit anti-rat monomeric TRAP (5a; 1:50) 5 for 30 min at room temperature (RT). Cells were washed and incubated with goat anti-rabbit ALEXA 488 (1:100; Molecular Probes, Cergy Pontoise, France; Invitrogen) for 30 min at RT. After washing, CD14-and TRAPpositive cells were detected using a FACSCalibur cytometer (BD Bioscience).
Secretion of TRAP from the human adipose tissue
Overall, 300 mg adipose tissue pieces were incubated at 37 1C in 3 ml Krebs-Ringer phosphate buffer (pH 7.4) supplemented with glucose (1 mg ml
À1
) and bovine serum albumin (10 mg ml À1 ) in a shaking water bath with air as the gas phase for various periods of time. Thereafter, the medium was removed and frozen in liquid nitrogen. It was kept at À70 1C for later protein determination. Methodological experiments validated this incubation system for studies of protein release in vitro, because secreted proteins display a linear increase with time during incubation. 28 In clinical needle biopsy experiments conducted on 24 obese and 22 lean subjects, 300 mg tissue pieces were incubated as described above for 2 h. The amount of protein secreted into the incubation medium was determined and related to tissue weight or number of fat cells, as described previously. 28 In brief, after weighing, incubated tissues were subjected to organic extraction and lipid content was determined. A separate piece of tissue was subjected to collagenase treatment, and the mean volume and weight of isolated fat cells was determined as described previously. 29 Thereafter, the number of incubated fat cells was obtained by dividing the incubated tissue lipid weight by the mean weight of isolated fat cells.
Measurement of total TRAP in incubation media using an in-house sandwich ELISA detecting total TRAP Polyclonal rabbit anti-rat recombinant total TRAP antiserum was generated as described previously, 27 and purified IgG antibodies were subsequently labeled with biotin using the Biotin Protein Labelling Kit (Roche, Bromma, Sweden) according to the manufacturer's protocol. For the enzyme-linked immunosorbent assay (ELISA), MaxiSorp 96-well plates (VWR, Stockholm, Sweden) were coated with 6 mg ml À1 unlabeled rabbit anti-rat recombinant total TRAP overnight in 0.1 M NaHCO 3 , pH 9.6 at 4 1C. Plates were washed three times with TBST (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween-20) and blocked with blocking solution (Thermo, Rockford, IL, USA) for 1 h in RT after which standards (Human recombinant TRAP; R&D Systems, Abingdon, UK) and samples were added and plates incubated overnight at 4 1C. Plates were then washed as described above three times, incubated with 1mg ml À1 biotinylated rabbit anti-rat recombinant total TRAP IgG for 1 h at RT and washed again as described above before incubation with streptavidin AP (Roche) diluted 1:5000 in TBST for 1 h at RT. After washing as described above, plates were developed using 10 mM para-nitrophenylphosphate (Fluka, Stockholm, Sweden) diluted in substrate solution (500 mM Tris-HCl pH 9.1, 2 mM MgCl 2 ) until color appeared. Color was read at 405 nm and a 4-parametric fit was used as standard curve fit.
Measurement of TRAP 5b in incubation media
Measurement of TRAP 5b was performed using BoneTRAP Assay (IDS Ltd, Boldon, UK) according to the manufacturer's protocol.
Measurement of adiponectin, glycerol, TNFa and IL-6 media in incubation media
Commercial ELISAs were used to determine TNFa, IL-6 and adiponectin as described previously. 28, 30 Glycerol (lipolysis index) was determined by bioluminescence assay. 31 Owing to the limited amount of samples, it was not possible to measure all compounds in all subjects.
Statistics
Values are shown as mean ± s.d. Data were compared using paired or unpaired t-test by linear regression analysis and by analysis of variance (repeated measure).
Results
ATM displays the highest cellular expression of TRAP mRNA in the human adipose tissue The expression of TRAP in mature adipocytes and separated cells from the SVF of human subcutaneous adipose tissues was analyzed using real-time quantitative PCR. In the human adipose tissue, ATMs are the primary source of TRAP mRNA, whereas only background levels of TRAP mRNA were found in mature adipocytes, adipocyte progenitor cells, endothelial cells and cells negative for CD34, CD31 and CD14 (mainly lymphocytes and mast cells; Figure 1 ). No statistically significant differences were found in TRAP transcript levels when comparing adipose tissue-derived cells originating from lean or obese subjects.
ATM expresses the TRAP 5a protein Flow-cytometry analyses performed on the SVF of human subcutaneous adipose tissues using CD14 antibodies showed TRAP secretion in the human adipose tissue P Lång et al that B31% of cells in the SVF fraction was positive for CD14 (Figures 2a and b) . Analysis using total or monomeric TRAP antibodies showed that monomeric and total TRAP, respectively, were present within almost all CD14 þ cells (Figures 2c and d) .
Development of an in-house sandwich ELISA for detection of total TRAP A typical standard curve of the in-house sandwich ELISA for total TRAP is shown in Figure 3a . To investigate the linear range, a four-parametric fit was applied showing that standard curves were linear in the investigated region at least up to 25 ng ml À1 TRAP. The lower detection limit was calculated from four independent standard curves ( Figure 3a; two replicates of each concentration/standard curve) by calculating the concentration given by the mean optical density of the concentration 0 ng l À1 þ 4 s.d. The lower detection limit from the four standard curves was 0.133 ± 0.181 ng ml
À1
. The coefficient of variance (percentages) for duplicate determination of independent adipose secretion (n ¼ 23) samples was calculated according to the formula: (mean of s.d. of the duplicates divided by grand mean of the duplicates) multiplied by 100, with a variance of 11%. Measurement of total TRAP secretion by the in-house sandwich ELISA from pieces of human subcutaneous adipose tissues in an explant system showed that total TRAP is secreted in a time-dependent manner (r 2 ¼ 0.82; Figure 3b) from human subcutaneous adipose tissues.
Secretion of TRAP from the human subcutaneous adipose tissue is correlated with adipose cellularity and adipose tissue morphology Measurement of total TRAP (TRAP 5a þ 5b) and TRAP 5b secretion from pieces of the human subcutaneous adipose tissue in an explant system revealed that TRAP 5b, measured using a commercially available ELISA specific for TRAP 5b, was not detectable (data not shown), whereas total TRAP was secreted in a time-dependent manner from the human subcutaneous tissue (Figure 3b ). Total TRAP secretion showed no difference in lean versus obese subjects when normalized against the lipid content of the adipose tissue (Figure 4a ). TRAP secretion in the human adipose tissue P Lång et al However, if normalized against adipocyte cell number, total TRAP secretion was significantly increased by B1.5-fold in obese versus lean subjects (Figure 4b ). The latter model of secretion was also positively correlated with fat cell size (Figure 4c ). In addition, total TRAP was also positively correlated with adipose morphology measured as morphology value (Figure 4d ), which is a method used to describe adipocyte volume 26 in which positive values classify hypertrophic adipocytes and negative values classify hypotrophic adipocytes. Total TRAP secretion per unit weight of the adipose tissue did not correlate significantly with fat cell size or morphology value (data not shown).
TRAP is secreted from the human adipose tissue in vivo Measurement of total TRAP in an in vivo model of human adipose tissue secretion showed that levels of TRAP were significantly (P ¼ 0.001) increased in the abdominal subcutaneous vein than in the arterialized peripheral vein ( Figure 5 ). This difference was observed in all individuals (n ¼ 8). This clearly indicates that TRAP is secreted from the human adipose tissue in vivo. Unfortunately, the number of subjects investigated was too small to allow a separate analysis of lean and obese subjects and the influence of sex. The correlation between the secretion of total TRAP from the human subcutaneous adipose tissue and known mediators connected to the low-grade inflammatory status of obesity and insulin resistance, such as TNFa, IL-6 and adiponectin, was investigated. Results revealed that secretion of total TRAP was positively and significantly correlated with secretion of cytokines TNFa and IL-6 (Figures 6a and b) . On the other hand, total TRAP secretion was not correlated with anti-inflammatory adipokine adiponectin (Figure 6c ) or with glycerol produced by lipolysis (Figure 6d ).
Discussion
Tartrate-resistant acid phosphatase may be an important factor in the development of obesity by regulating adipogenesis. It is expressed in the adipose tissue and overexpression causes obesity in mice. Moreover, TRAP is overexpressed in the adipose tissue of obese humans. 10 The cellular origin of TRAP in the adipose tissue is not fully settled, although total TRAP and TRAP 5a co-localized with the monocyte/macrophage marker CD68. 10 However, as CD68 is also expressed by other cell types besides macrophages, 32 we determined the expression pattern of TRAP in different cells of the human adipose tissue. Separation of different cell types by immunodepletion/selection, followed by TRAP mRNA quantification revealed that TRAP is highly expressed per cell in ATMs compared with mature adipocytes, adipocyte progenitor cells, endothelial cells and cells negative for CD34, CD14 and CD31 in both lean and obese subjects. Co-localization of total TRAP and TRAP 5a with CD14 þ cells using TRAP secretion in the human adipose tissue P Lång et al fluorescence-activated cell sorting analysis revealed that most of the CD14 þ population is positive for intracellular TRAP protein, indicating that not only TRAP mRNA but also TRAP protein expression is present in ATMs. It is also indicated by the use of the specific TRAP 5a antibody that the ATM TRAP protein at least partly consists of TRAP 5a, which is the isoform suggested to be responsible for regulation of adipogenesis. 10 As no TRAP 5b-specific antibody was available, it was not possible to elucidate the relative proportion of staining seen with total TRAP antibodies that were derived from TRAP 5b. However, this isoform was suggested not to have any effect on adipogenesis. 10 As no difference in the expression of TRAP per macrophage between lean and obese subjects could be detected, the previously reported increase in TRAP 5a in the adipose tissue of obese subjects 10 is likely to originate from the increase in numbers of TRAP-expressing macrophages rather than an increased cellular expression. That the expression of TRAP is a marker for macrophage burden rather than activation has also been suggested in patients with rheumatoid arthritis. 13 These data support our original hypothesis that in the human adipose tissue, TRAP 5a is secreted from macrophages acting on adipocytes in a paracrine manner. 10 Here, we have studied whether TRAP is a true adipokine and also whether the levels of this adipokine were influenced by obesity-related factors. To define TRAP as an adipokine, we developed a sensitive ELISA for human total TRAP, which displayed a lower detection limit of 0.133 ng ml À1 . The coefficient of variance of adipose tissue TRAP secretion was 11%, which is within the acceptable range. 33 Unfortunately, there are no commercial assays for TRAP 5a yet available, which seems to be the most important isoform of TRAP involved in adipogenesis. 10 However, in human adipose tissues in vitro, it was not possible to detect TRAP 5b secretion using a commercially available ELISA by specifically measuring TRAP 5b enzyme activity using the difference in pH optimum between 5a and 5b. Therefore, our data strongly suggest that TRAP 5a and possibly also TRAP 5b is present intracellularly in ATMs. However, TRAP 5a is likely the predominant TRAP isoform secreted from ATMs or any other cell type present in human adipose tissues. The secretion of total TRAP from the human adipose tissue was not influenced by obesity if normalized against lipid weight. However, if normalized against total number of fat cells in the biopsy, total TRAP was increased in subcutaneous adipose tissues derived from obese compared with lean subjects. Furthermore, when expressed per number of fat cells, but not per weight unit of tissue, TRAP correlated positively with fat cell size and with adipose morphology (in Figure 4d , negative values indicate different degrees of hyperplasia and positive values indicate different degrees of hypotrophy). These data with fat cell size and number suggest that TRAP secretion is increased when the tissue consists of mainly large fat cells, that is, hypertrophy. Thus, although TRAP is produced by macrophages and is not increased when identical amounts of adipose tissues of lean and obese are compared, our findings point at a correlation between adipose morphology and TRAP secretion. As we did not quantify macrophage number in the adipose tissue, it is not possible to relate our results to infiltration of these cells. However, it has been shown by others 15 that there is a positive correlation between fat cell size and the amount of macrophages present in the adipose tissue. These relationships between adipose cellularity (fat cell size and number) and total TRAP secretion in combination with the lack of TRAP 5b secretion strongly support the previous notion that TRAP 5a is important for human adipogenesis 10 and possibly involved in the increased adipogenesis observed in obese humans. 34 Here, we demonstrate that total TRAP is a novel human adipokine, that is, it is secreted from the human adipose tissue in a time-dependent manner in vitro. It is also secreted in the overnight fasted state from human adipose tissues in vivo, as evident from comparison of levels in the abdominal subcutaneous blood versus arterialized blood. In addition, total TRAP secretion from the subcutaneous adipose tissue was found to be positively correlated with proinflammatory mediators such as TNFa and IL-6 known to be associated with the low-grade inflammatory status of obesity as reviewed in 35, 36 but not with the anti-inflammatory adipokine adiponectin or with lipolysis. These findings strengthen the hypothesis that TRAP is associated with the macrophage population in obesity. Still, even though adipose tissue secretion of TRAP seems to be correlated with proinflammatory cytokines in the obese state, these mediators might not to be fully associated in all stages of the disease as serum levels of TRAP, in contrast to those of TNFa and IL6, were not reduced by exercise. 11 However, it remains to be investigated whether TRAP serum levels are correlated with the number of ATMs. This might indicate that TRAP is expressed and secreted by a different functional macrophage population than TNFa and IL-6, making the future characterization of the TRAP-expressing macrophage population highly relevant. These different functional macrophage populations might then contribute to different events occurring in the human adipose tissue in which the TNFasecreting population would inhibit adipogenesis and induce insulin resistance, whereas the TRAP 5a-secreting macrophage would induce differentiation of insulin-sensitive adipocytes as supported by previous findings in the TRAP transgenic mouse model. 10 This study was conducted on the abdominal subcutaneous adipose tissue, which is the body's largest adipose region. At present, we have not assessed whether there are site variations in the expression and secretion of TRAP in different adipose sites. Furthermore, the influence of obesity-related parameters on TRAP was only investigated in pre-menopausal women. Therefore, at the moment, we cannot discern whether there exist possible gender or age differences in the expression and secretion of TRAP from the adipose tissue. In summary, TRAP seems to be a novel human adipokine, which is secreted from abdominal subcutaneous adipose TRAP secretion in the human adipose tissue P Lång et al tissues both in vivo and in vitro. The highest TRAP expression per cell is found in macrophages in human adipose tissues, and these ATMs most likely secrete TRAP 5a but not TRAP 5b. Furthermore, total TRAP (most likely 5a) secretion from human adipose tissues is positively related to fat cell size and number, as well as to adipose tissue secretion of proinflammatory mediators (that is, TNFa and IL-6), supporting the notion that monomeric TRAP is important for regulation of fat mass and the inflammatory status of the adipose tissue.
